Clinical Trials Logo
  1. Home
  2. Advanced Colorectal Cancer
  3. NCT02619435

Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer — STREAM  

Advanced Colorectal Cancer Clinical Trial

Official title:
Regorafenib Monotherapy as Second-line Treatment of Patients With RAS-mutant Advanced Colorectal Cancer: a Multicentre, Single-arm, Two-stage, Phase 2 Study

Clinical Trial Summary

The purpose of this study is to purpose of this study is to assess if regorafenib is active enough, in terms of 6-month progression-free rate, to warrant further comparative studies in patients with RAS-mutant advanced colorectal cancer who have progressed after first-line oxaliplatin-based chemotherapy plus bevacizumab.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02619435
Study type Interventional
Source National Cancer Institute, Naples
Contact
Status Active, not recruiting
Phase Phase 2
Start date November 2015
Completion date November 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05028933 - IMC001 for Clinical Research on Advanced Digestive System Malignancies Phase 1
Recruiting NCT06200363 - A Clinical Study of T3011 in Combination With Regorafenib in Patients With Advanced Colorectal Cancer Phase 1
Not yet recruiting NCT02923622 - Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer N/A
Completed NCT01723969 - Screening Platform for Clinical Trials in Advanced Colorectal Cancer
Active, not recruiting NCT00309179 - A Phase II Study of the Safety and Efficacy of E7820 Plus Cetuximab in Colorectal Cancer, Preceded by a Run-in Study in Advanced Solid Tumors Phase 2
Completed NCT03699111 - Identification of New Patient Stratification Tools in MSS RAS mt mCRC
Not yet recruiting NCT02826837 - LEAC-102 for Advanced Colorectal Cancer Phase 1/Phase 2
Recruiting NCT05077839 - Trifluridine/Tipiracil Combined With Oxaliplatin and Bevacizumab Versus XELOX Plus Bevacizumab in mCRC Phase 2
Recruiting NCT04324476 - A Study of Bevacizumab Plus XELOX/XELIRI for First-line Treatment in Unresectable Advanced Colorectal Cancer Phase 2
Not yet recruiting NCT06369259 - Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer Phase 2
Completed NCT00707889 - Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer Phase 2
Terminated NCT01271166 - Glivec® Plus m-FOLFOX Avastin® in Advanced Colorectal Cancer Phase 1
Completed NCT00386828 - Chemoradiation for Locally Advanced and Low Rectal Cancers: Avastin-Capecitabine-Oxaliplatin-Radiation REctal Cancer Trial Phase 2
Recruiting NCT04764006 - Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study Phase 2
Active, not recruiting NCT04835324 - Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
Completed NCT01822444 - ANGIOPREDICT. ICORG 12-16, V3
Completed NCT00498407 - A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer Phase 2
Recruiting NCT05731336 - A Prospective Cohort Study of Advanced Colorectal Cancer Treated With Oxaliplatin and Irinotecan.
Active, not recruiting NCT04744831 - Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer Phase 2
Terminated NCT03311750 - Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer Phase 2